Logo

Exelixis and Daiichi Report Launch of Minnebro (Esaxerenone) Tablets for Hypertension in Japan

Share this

Exelixis and Daiichi Report Launch of Minnebro (Esaxerenone) Tablets for Hypertension in Japan

Shots:

  • The approval of Minnebro (Esaxerenone) tablets (1.25/2.5/5 mg) is based on P-III ESAX-HTN study in patients with hypertension- with its regulatory approval submitted to MHLW in Feb’18
  • In Q2’19- Exelixis will receive $20M as milestone payment from Daiichi- as per their research collaboration for the development of therapies targeting mineralocorticoid receptor signed in 2006
  • Minnebro (Esaxerenone) tablets are mineralocorticoid receptor blocker targeted to treat patients with hypertension- and is currently evaluated in P-III ESAX-DN study for patients with diabetic nephropathy by Daiichi in Japan

Ref: Exelixis | Image: Brand Navigation

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions